Patent ID: 9119868
Filing Date: 2015-09-01
Classification: A61K,A61P

Abstract:
1. A method of treatment of Hepatitis C Virus (HCV) in a human in need thereof comprising administering to the human a compound of the structure: or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from the group consisting of: an HCV NS2 protease inhibitor, an HCV NS3/4A protease inhibitor, an HCV NS3 helicase inhibitor, an HCV NS4B replication factor inhibitor, an HCV NS5A replication factor inhibitor, an HCV NS5B polymerase inhibitor, an HCV entry inhibitor, an HCV internal ribosome entry site inhibitor, a microsomal triglyceride transfer protein inhibitor, an α-glucosidase inhibitor, a caspase inhibitor, a cyclophilin inhibitor, an immunomodulator, a metabolic pathway inhibitor, an interferon, and a nucleoside analogue.